Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Aurora Yuzu Lemon Pastilles, CBD THC 5mg/pastille, 30pk, MedReleaf Australia, CON-1190
Product name
Aurora Yuzu Lemon Pastilles, CBD THC 5mg/pastille, 30pk
Sponsor name
MedReleaf Australia
ARTG
Consent start
Consent no.
CON-1190
Standard
paragraph 13(3)(f) of Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017
Non-compliance with standard
The non-compliance arises because the medicinal cannabis products are
manufactured at a site in Canada that does not currently hold the evidence
listed in paragraph 13(3)(c) of TGO 93, including written confirmation from
Health Canada that the manufacturing site operates in accordance with Part 5:
Good Production Practices of the Cannabis Regulations SOR/2018-144 (Canada), as
in force or existing from time to time, and either a valid certificate of good
manufacturing practice issued to the manufacturer of the product by a licensing
authority of an EU Member State; or written confirmation from the Therapeutic
Goods Administration (TGA) that the manufacturing site operates in accordance
with the PIC/S Guide to GMP.
Conditions imposed
1. MedReleaf Australia shall notify the TGA, by email at the time the goods are
imported into Australia, of the following information in relation each
therapeutic good subject to this consent:
a. the product name and presentation;
b. batch/lot number;
c. expiry date; and
d. number of units imported into Australia.
Therapeutic product type
Other therapeutic goods non-approved